MRNA therapy takes on hormone deficiency

NCT ID NCT07197450

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests an mRNA drug called XH02 in 6 adults with hypoparathyroidism, a condition where the body lacks parathyroid hormone (PTH). The drug is designed to instruct cells to produce PTH after being given through a vein. The main goal is to check safety, while also measuring hormone and mineral levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mRNA drug XH02 (PTH1-84 mRNA)

What this could lead to

If it works, this could point toward a new way to treat hypoparathyroidism by replacing the missing hormone without daily injections.

What could go wrong

This is a very early, tiny trial with only 6 people. It is mainly checking safety, not yet proving the drug works. The approach is new and may fail or cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, 100730, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact